Kuva Labs and Lisata Therapeutics confirmed May 29 that the formal tender offer period is under way for Kuva's acquisition of the $47 million market-cap oncology company. The deal, announced in April, values Lisata at $1.85 per share in cash and stock, a 43% premium to the 30-day volume-weighted average before rumors surfaced. Kuva Acquisition, the wholly owned merger subsidiary, is the tendering vehicle. The offer expires June 26 unless extended.
Lisata's sole clinical asset is certepetide, a tumor-penetration peptide in Phase 3 trials for pancreatic cancer in combination with standard chemotherapy. The company burned $18.3 million in cash through the first nine months of 2025 and held $22.1 million in cash and equivalents at quarter-end. Kuva, a Nashville-based biotech holding company with no marketed products, is using the acquisition to fold Lisata's clinical infrastructure and Nasdaq listing into its portfolio strategy. Management has not disclosed the financing structure behind the cash component, but Kuva's prior capital raises were sub-$15 million rounds from regional family offices and healthcare-focused funds.
The tender bypasses a traditional shareholder vote. If Kuva secures more than 50% of Lisata shares by expiration, the second-step merger follows within days under Delaware law. Lisata's board unanimously recommended acceptance. The company's top three institutional holders—Armistice Capital, Invenomic Capital Management, and Vanguard—collectively own 31% of shares. None have filed 13D amendments indicating acceptance or rejection. Two governance advisories, ISS and Glass Lewis, have not yet published opinions, but both typically favor management-endorsed cash premiums above 30% when no competing bid surfaces.
Operators should watch for the mid-June tender tally, typically disclosed within three business days of the halfway mark. If Kuva has not crossed 50% by June 19, extension language will appear in an 8-K. Lisata's Phase 3 data readout was originally scheduled for Q3 2026, but the trial's independent monitoring committee has discretion to pause enrollment during ownership transition. That decision, if it occurs, surfaces in an amended protocol filing with FDA, usually within 21 days of board resolution. Kuva has not stated whether it will continue the trial or restructure it post-close.
The Lisata board set the record date at May 22. Shares tendered after that date require broker medallion guarantees, which slows retail participation. Institutional desks have until 5:00 PM Eastern on June 26 to deliver stock certificates to the depositary, Computershare Trust Company. Kuva's legal counsel is Troutman Pepper; Lisata is advised by Goodwin Procter.